ospemifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives 4749 128607-22-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • osphena
  • FC-1271a
  • ospemifene
  • senshio
an estrogen agonist/antagonist with tissue selective effects, its biological actions are mediated through binding to estrogen receptors, this binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism)
  • Molecular weight: 378.90
  • Formula: C24H23ClO2
  • CLOGP: 5.56
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 29.46
  • ALOGS: -5.86
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
fu (Fraction unbound in plasma) 0 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,STK33,TEK,TGFBR1,TTK 38
kinase-selectivity-class GRK2,PDK4 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Feb. 26, 2013 FDA SHIONOGI INC
Nov. 20, 2014 EMA Shionogi Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hot flush 310.13 36.75 87 1351 59401 90567608
Labelled drug-drug interaction medication error 193.10 36.75 45 1393 14537 90612472
Vaginal discharge 165.25 36.75 42 1396 19422 90607587
Vaginal haemorrhage 127.85 36.75 38 1400 31233 90595776
No adverse event 113.47 36.75 42 1396 67940 90559069
Therapeutic response unexpected 104.43 36.75 30 1408 21850 90605159
Muscle spasms 99.47 36.75 57 1381 251826 90375183
Vulvovaginal burning sensation 73.59 36.75 15 1423 2580 90624429
Vulvovaginal discomfort 67.18 36.75 14 1424 2683 90624326
Inability to afford medication 57.60 36.75 13 1425 3609 90623400
Hyperhidrosis 51.33 36.75 30 1408 136275 90490734
Vulvovaginal pruritus 51.04 36.75 12 1426 3981 90623028
Off label use 45.56 36.75 70 1368 1102182 89524827
Labelled drug-disease interaction medication error 38.96 36.75 6 1432 205 90626804
Product prescribing error 37.24 36.75 15 1423 30130 90596879
Vulvovaginal pain 36.94 36.75 9 1429 3465 90623544

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hot flush 240.47 41.91 65 967 65971 110522296
Vaginal discharge 121.11 41.91 29 1003 17879 110570388
Labelled drug-drug interaction medication error 111.64 41.91 30 1002 29272 110558995
Vaginal haemorrhage 101.79 41.91 27 1005 25047 110563220
Muscle spasms 86.86 41.91 45 987 278112 110310155
Therapeutic response unexpected 79.52 41.91 22 1010 23821 110564446
Vulvovaginal discomfort 64.96 41.91 12 1020 2112 110586155
No adverse event 55.11 41.91 22 1010 73817 110514450
Vulvovaginal burning sensation 52.57 41.91 10 1022 2059 110586208

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03XC05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Selective estrogen receptor modulators
FDA MoA N0000000168 Selective Estrogen Receptor Modulators
FDA EPC N0000175826 Estrogen Agonist/Antagonist
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50739 estrogen receptor modulator
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

G03XC Selective estrogen receptor modulators 4 drugs
bazedoxifenelasofoxifeneormeloxifeneraloxifene

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dyspareunia indication 71315007
Atrophic vulva indication 248861000 DOID:14275




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8236861 Aug. 11, 2026 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8236861 Aug. 11, 2026 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8236861 Aug. 11, 2026 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor MODULATOR IC50 6.08 WOMBAT-PK CHEMBL
Estrogen receptor beta Nuclear hormone receptor ANTAGONIST Ki 6.39 IUPHAR

External reference:

IDSource
D08958 KEGG_DRUG
4032347 VANDF
CHEBI:73275 CHEBI
CHEMBL2105395 ChEMBL_ID
C119141 MESH_SUPPLEMENTAL_RECORD_UI
7349 IUPHAR_LIGAND_ID
DB04938 DRUGBANK_ID
B0P231ILBK UNII
1370971 RXNORM
199207 MMSL
29311 MMSL
d08070 MMSL
014918 NDDF
716223004 SNOMEDCT_US
C1313616 UMLSCUI
7859 INN_ID
3036505 PUBCHEM_CID
B0P231ILBK INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Osphena HUMAN PRESCRIPTION DRUG LABEL 1 55494-580 TABLET, FILM COATED 60 mg ORAL NDA 30 sections